Can a Genetic Variation in the Vitamin D Receptor Protect Against Osteoporosis?

PRLog (Press Release) - Nov. 29, 2012 - Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2156, vcohn@liebertpub.com

Can a Genetic Variation in the Vitamin D Receptor Protect Against Osteoporosis?

New Rochelle, NY—Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency. A modified form of the vitamin D receptor present in some individuals may lower their risk for developing osteoporosis, according to an article in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com).  The article is available on the Genetic Testing and Molecular Biomarkers website (http://www.liebertpub.com/gtmb).

To act on cells in the body, vitamin D binds to a specific receptor on the surface of cells. A variation in the gene for the vitamin D receptor (called the Bsm I polymorphism) may change this interaction. In the article, “Vitamin D Receptor BSM I Polymorphism and Osteoporosis Risk: A Meta-Analysis from 26 Studies,” (http://online.liebertpub.com/doi/full/10.1089/gtmb.2012.0267) authors Fu Jia and colleagues, Kunming Medical University and Yunnan University of Chinese Traditional Medicine, Yunnan, People’s Republic of China, report that people with this genetic variation appear to have a significantly decreased risk of developing osteoporosis.

“This meta-analysis provides a pathway to help determine the likelihood that a person may develop osteoporosis and is a good example for the potential application of genetics to clinical medicine,” says Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers, and Director of the University of Florida’s Genetics Institute, College of Medicine, Gainesville, FL.

About the Journal
Genetic Testing and Molecular Biomarkers (http://www.liebertpub.com/gmtb) is an authoritative peer-reviewed journal published 12 times per year in print and online that reports on all aspects of genetic testing, including molecular and biochemical based tests and varied clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. Tables of content and a free sample issue may be viewed on the Genetic Testing and Molecular Biomarkers website (http://www.liebertpub.com/gmtb).

About the Publisher
Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).

Photo:
http://www.prlog.org/12033303/1